Seeking Alpha

It has taken a little longer than I might have liked, but my bullish call on AtriCure (ATRC) has been working out pretty well this year, with the shares up more than 100% over the past year and on a year-to-date basis. I believe the Street has been responding to a strong uptick in the company's growth rate, but I also believe that significant management turnover over the past year or so (including a new CEO, SVP, and VPs of marketing and R&D) has rebuilt confidence that AtriCure may at last have a winning strategy.

With the shares having doubled, "now what?" seems like a fair question. I am hesitant to chase off current shareholders, as though...

Only subscribers can access this article, which is part of the PRO research library covering 3,760 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: